[
  {
    "ts": null,
    "headline": "ResMed initiated with an Overweight at Morgan Stanley",
    "summary": "Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a market-leading position in the obstructive sleep apnea market and valuations appear attractive at current levels, with a strong balance sheet position and the highest ROIC across the firm’s Australian Healthcare industry sector coverage, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial",
    "url": "https://finnhub.io/api/news?id=e5300609d85e5e26b59526ae3e44078e3880901d3e3e285fb085cfa252ec3056",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742480109,
      "headline": "ResMed initiated with an Overweight at Morgan Stanley",
      "id": 133326556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a market-leading position in the obstructive sleep apnea market and valuations appear attractive at current levels, with a strong balance sheet position and the highest ROIC across the firm’s Australian Healthcare industry sector coverage, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial",
      "url": "https://finnhub.io/api/news?id=e5300609d85e5e26b59526ae3e44078e3880901d3e3e285fb085cfa252ec3056"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Health Care Fund Q4 2024 Commentary",
    "summary": "Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.",
    "url": "https://finnhub.io/api/news?id=8f81827abb6ec00be306ef52a83e31acbe2c243bf3d6f7d992305822a81d2a8e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742461500,
      "headline": "Invesco Health Care Fund Q4 2024 Commentary",
      "id": 133273550,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
      "related": "RMD",
      "source": "SeekingAlpha",
      "summary": "Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.",
      "url": "https://finnhub.io/api/news?id=8f81827abb6ec00be306ef52a83e31acbe2c243bf3d6f7d992305822a81d2a8e"
    }
  }
]